Generation Bio Appoints Dannielle Appelhans to Its Board of Directors
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors.
- CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors.
- Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations.
- Generation Bios aim to create novel genetic medicines for therapeutic areas previously inaccessible via conventional approaches is highly compelling, Appelhans said.
- Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.